Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma

NCT02197221 is registered in ClinicalTrials.gov with University Hospital, Toulouse as lead sponsor.

NCT NCT02197221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02197221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Lead sponsor
University Hospital, Toulouse
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2015
Completion date
December 31, 2018
Enrollment
300 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma